biid
$AYTU This company's story has changed since the acquisition of EXXUA. It is very likely the best-in-class drug in Major Depressive Disorder (MDD) -- which has a $22.0B US market -- with no sexual or weight gain side-effects. The company's legacy portfolio's sales remain robust and allow the company to focus on EXXUA sales, which keep going up quarter-to-quarter. Exciting times for the company as it grows and finally provides real shareholder value.
5
